Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted conditional marketing authorization for DURVEQTIX (fidanacogene elaparvovec), a gene therapy for the treatment of...
SOPA Images / Contributor / Getty Images
Key TakeawaysAstraZeneca's second-quarter earnings beat expectations Thursday, and the drugmaker also lifted its guidance.Like its COVID-19...
The Media's Latest Pathetic Blame Game
Authored by Ian Miller via The Brownstone Institute,
By late 2020, the media and public health establishment had two obsessions.
One of their...
Pfizer's Phase 3 AFFINE study of giroctocogene fitelparvovec gene therapy for hemophilia A meets key endpoints, showing a significant reduction in annualized bleeding rate.
read more...
The hemophilia A treatment could become the company's second gene therapy to enter the U.S. market after Beqvez, which was cleared in April for hemophilia B...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene therapy for the treatment...
'Pure Blood': Dating Divide Over Vaccination Status Splits Those Looking For A Partner
Authored by Allan Stein via The Epoch Times (emphasis ours),
Courtney Furlong, 36, had always...
Pharmaceutical giants like Roche, Eli Lilly, Novo Nordisk, and Pfizer are racing to develop oral weight loss medications. These drugs promise to complement existing injectables, offering new hope in...